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In this study, we assessed the role of melanocortin 1 receptor (MC1R) variants and of two patched (PTCH)
polymorphisms (c.3944C4T (P1315L), insertion 18 bp IVS1-83) as risk factors for basal cell carcinoma (BCC) in
the French population. The population investigated comprised 126 BCC patients who were enrolled on the
basis of specific criteria (multiple and/or familial BCC and/or onset before the age of 40 years and/or association
with another tumor) – and 151 controls matched for ethnicity, age, and sex. MC1R variants appeared as a
moderate risk factor for BCC (odds ratio (OR) for one and two variants, 2.17 [1.28–3.68] and 7.72 [3.42–17.38],
respectively), independently of pigmentation characteristics (OR¼ 2.53 [1.34–4.8]). Interestingly, in addition to
the predictable red hair color (RHC) alleles, two non-RHC alleles (V60L and V92M) were also closely associated
with BCC risk (OR 3.21 [1.91–5.38] and 2.87 [1.5–5.48], respectively), which differs from the situation in the Celtic
population. In addition, the PTCH c.3944C/C genotype was also associated with BCC risk (OR 1.94 [1.2–3.1]),
especially in the subgroup of patients with multiple tumors (OR 2.16 [1.3–3.6]). Thus, our data show that MC1R
and PTCH variants are associated with BCC risk in the French population. We further suggest that assessing
MC1R and PTCH status could be useful, combined with the assessment of clinical risk factors, in identifying
high-risk patients to be targeted for prevention or more rigorous surveillance.
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INTRODUCTION
Basal cell carcinoma (BCC) is the commonest cancer in the
Caucasian population, accounting for 29% of all cancers
(DePinho, 2000). Its incidence is increasing (Wong et al.,
2003), and it constitutes an important public health problem.
Solar UVR has been shown to be the main environmental
causative factor of BCC (Kricker et al., 1994). Other BCC risk
factors include phenotypic traits such as red hair, freckles, fair
skin that does not readily tan, and a family history of skin
cancer (Naldi et al., 2000).
Genetic factors also mediate BCC risk.
Basal cell nevus syndrome, an autosomal dominant
disorder comprising developmental defects and multiple
BCCs, has been linked to inactivating mutations in the
patched (PTCH) gene, shedding some light on the crucial
importance of the PTCH/sonic hedgehog pathway in BCC
pathogenesis (Hahn et al., 1996; Gorlin, 2004). In addition,
recent data has suggested that PTCH polymorphism may also
be associated with BCC risk (Strange et al., 2004a, b; Asplund
et al., 2005). Notably, the PTCH variant c. 3944C (1315Pro)
may confer an increased population risk for BCC and an
increased individual risk for multiple BCC (Asplund et al.,
2005).
BCC susceptibility has also been shown to be mediated by
defects in the nucleotide excision repair system (either severe
deleterious mutations giving rise to xeroderma pigmentosum
(Magnaldo and Sarasin, 2004), or less deleterious variants in
XPD or ERCC2 genes (Han et al., 2004; Lovatt et al., 2005)).
In addition, BCC formation is also influenced by polymorph-
ism of genes encoding detoxifying enzymes (glutathione S-trans-
ferase, cytochrome P450) (Lear et al., 1996; Ramachandran
et al., 2001), and in a key gene involved in pigmentation,
the melanocortin 1 receptor (MC1R) (Bastiaens et al., 2001;
Box et al., 2001).
MC1R is a seven-pass transmembrane G-protein coupled-
receptor consisting of 317 amino acids, which is expressed in
melanocytes and keratinocytes (Chhajlani, 1996). Stimulation
of MC1R by a-melanocyte-stimulating hormone (a-MSH)
leads to enhanced adenylate cyclase and cAMP activity,
resulting in the synthesis of the black photoprotective
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pigment eumelanin rather than of the non-protective red
pigment phaeomelanin (Sturm et al., 2003b). MC1R is highly
polymorphic in Caucasian populations, and numerous MC1R
variants have been demonstrated to lead to a loss of function,
decreasing either cAMP production or a-MSH binding affinity
(Frandberg et al., 1998; Schioth et al., 1999; Healy et al., 2001;
Jimenez-Cervantes et al., 2001a, b; Ringholm et al., 2004).
Four MC1R variants alleles (R142H, R151C, R160W, and
D294H) have been shown to be associated with the red hair
and fair skin phenotype (red hair color (RHC)) that is
characterized by fair pigmentation (fair skin, red hair and
freckles) and sun sensitivity (Sturm, 2002; Rees, 2004).
Subsequently, loss-of-function variants of MC1R have been
shown to play an important role in determining the risks of
melanoma and non-melanoma-skin cancer (reviewed in
Sturm et al., 2003a). Three studies in particular have
previously demonstrated that there is an association between
BCC risk in populations of Celtic origin with three MC1R
RHC alleles (R151C, R160W, D294H) (Bastiaens et al., 2001;
Box et al., 2001; Dwyer et al., 2004).
The aim of this work was to assess simultaneously the role of
MC1R and of PTCH polymorphisms as BCC risk factors in an
ethnically-distinct population by means of a case control-study.
RESULTS
Clinical BCC risk factors
The clinical characteristics of all BCC patients and controls
are summarized in Table 1. All the classical clinical risk
factors (skin types I–II, light eye and hair colors, and solar
lentigines) were strongly associated with BCC (Pp0.0001,
odds ratio (OR) ranging from 2.98 to 4.91).
Frequency of MC1R variants and effect on BCC risk
Nineteen non-synonymous MC1R variant alleles were
identified (Table 2), 15 of which were classified as functional
(see Materials and Methods and Table 2). These included
three previously unreported MC1R variants (N118K, N281S,
and R306H).
Initially, in order to study the effect of MC1R, all
‘‘functional’’ variants (RHC and non-RHC) were pooled
(Total type–II variants, Table 2). MC1R variants were
significantly more frequent in the BCC patients, and there
was a gene dosage effect on BCC risk (OR of 2.17 for one
variant and 7.72 for two variants, respectively, Table 3a).
When detailing our results, we observed that three variants
(two non-RHC: V60L and V92M and one RHC: R151C) were
significantly associated with BCC risk. One other RHC allele
(D294H) showed a nearly significant association, whereas
the two other RHC alleles (R142H, R160W) were not
associated with BCC risk (Table 2).
When RHC and non-RHC alleles were assessed sepa-
rately, we observed that both non-RHC and RHC alleles were
significantly associated with BCC risk (Table 3b).
Persistence of MC1R effect after stratification for pigmentation
characteristics
Table 4 shows the significant persistence of BCC risk
according to MC1R variants after stratification for all
categories of pigmentation characteristic (skin type, hair
color, eye color, solar lentigines). Notably, when two MC1R
variants were present, the risk of BCC was present both in
dark- or fair-pigmented individuals. When only one MC1R
variant was present, the effect was less pronounced. These
findings strongly suggest that MC1R variants constitute
independent risk factors for the development of BCC.
Distribution of MC1R variants in the different BCC subgroups
The prevalence of MC1R variants ranged from 63 to 80%
among the BCC subgroups (multiple BCC, BCC before the
age of 40 years, familial BCC, BCC associated with another
cancer), but there was no statistical difference between these
different categories. In addition, MC1R variant frequency was
not statistically different in patients with BCC localized only
Table 1. Clinical characteristics of patients with basal
cell carcinomas and controls
Clinical
characteristics BCC (126)
Controls
(151) P OR
Gender
Women 71 (56) 84 (56)
Men 55 (44) 67 (44) 0.86 NA
Mean age (years) 48 [24–91] 50 [19–100] NA
Skin type
III 33 (33) 62 (41) Ref.1
IV 3 (3) 33 (22)
I 11 (11) 6 (4) o0.0001 2.98
[1.77–5.01]
II 54 (53) 50 (33)
Hair color
Dark 17 (19) 47 (31) Ref.1
Dark brown 23 (24) 60 (40)
Blond 21 (23) 10 (7) 0.0001 3.38
[1.97–5.82]
Light brown 28 (30) 29 (19)
Red 4 (4) 4 (3)
Eye color
Dark 36 (37) 97 (65) Ref.
Light 61 (63) 53 (35) o0.0001 3.1
[1.83–5.26]
Lentigines
No 28 (29) 97 (67) Ref.
Yes 68 (71) 48 (33) o0.0001 4.91
[2.81–8.57]
OR=odds ratios are indicated with 95% CI; NA=not applicable;
Ref.=reference.
1OR calculation was performed by comparing light versus dark hair color,
and skin type I–II versus III–IV.
Significant associations are shown in bold characters.
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on sun-exposed sites (head and neck, limbs) or only on a less-
exposed site (trunk) (data not shown).
Distribution of PTCH polymorphisms among cases and controls
The distribution of genotypes of the PTCH single nucleotide
polymorphism rs357564 is shown in Table 5. This single
nucleotide polymorphism was in Hardy–Weinberg equili-
brium in both patients and controls, and showed a
significantly different distribution in BCC patients and
controls. Overall, the c.3944C/C genotype was significantly
more frequent in patients than in controls (51 vs 35%,
P-value¼0.007, OR 1.94 [1.2–3.1]).
Furthermore, this genotype was also more frequent in the
subgroup of patients with multiple BCCs (P¼ 0.003, OR 2.16
[1.3–3.6]), but not in that with a single BCC (P¼0.70). The
association with multiple tumors persisted in the subgroup of
15 patients with more than five tumors (Fisher’s exact
test¼ 0.024). On the other hand, this association was not
Table 2. Allelic frequencies of MC1R variants in BCC patients and control subjects
BCC (n=252) Controls (n=302) P OR [95% CI]
MC1R consensus 125 (49.6) 220
MC1R variants type 1
R163Q 10 (4) 8 (2.6)
T95M 0 1
V180L 0 1
R223Q 1 0
Total MC1R wt 135 (53.6) 230 (76.5) Ref. 1
MC1R variants type 2
V60L1,2 49 (19.4) 26 (8.6) 0.0001 3.21 [1.91–5.38]
S83P2,3 0 1 NA NA
D84E2–4 0 2 NA NA
V92M5 27 (10.7) 16 (5.3) 0.001 2.87 [1.5–5.48]
V92L5 0 1 NA NA
N118K3 1 0 NA NA
V122M5 0 1 NA NA
R142H1–3,5 4 (1.6) 2 (0.7) 0.096 3.40 [0.62–18.8]
R151C1–4 14 (5.5) 5 (1.6) 0.00076 5.11 [1.82–14.4]
I155T2,3 2 (0.8) 2 (0.7) NA NA
R160W1,2,4 11 (4.4) 11 (3.6) 0.22 1.66 [0.7–3.93]
N281S3 1 0 NA NA
D294H1–5 7 (2.7) 4 (1.3) 0.0536 2.98 [0.86–10.37]
R306H3 1 0 NA NA
Ins 867 1 1 NA NA
Total variants type II 117 (46.4) 72 (23.5) o0.0001 2.77 [1.93–3.97]
NA=not applicable; Ref.=reference.
Significant associations are shown in bold characters.
Type I variants may not modify MC1R function as these variants have not been previously associated with melanoma, and have not been tested in functional
assays (see Statistical analyses in the Materials and Methods section). These variants are pooled with the MC1R consensus sequence, and considered as wild
type in Statistical analyses.
Type II variants have been shown to result in diminished MC1R function, and/or associated with fair pigmentation characteristics (Sturm, 2002), and/or
strongly associated with the risk of skin cancer in previous studies.
New variants that have not been previously identified are shown in italic characters. ORs are indicated with 95% CI.
1MC1R variants are unable to stimulate cAMP production as strongly as the wild-type receptor in response to a-MSH stimulation (Frandberg et al., 1998;
Healy et al., 2001; Jimenez-Cervantes et al., 2001a, b; Schioth et al., 1999).
2MC1R variants previously shown to be associated with the RHC phenotype (reviewed in (Sturm, 2002)).
3MC1R variants predicted to be damaging by the Polyphen program.
4MC1R variants previously shown to be associated with melanoma risk (Kennedy et al., 2001; Palmer et al., 2000; Valverde et al., 1996).
5MC1R variants showing a decreased a-MSH-binding affinity (Jimenez-Cervantes et al., 2001a).
6Fisher’s exact test.
7MC1R single nucleotide insertion producing a frameshift mutation that results in a prematurely terminated, non-functioning receptor.
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seen either in patients who developed BCC before the age of
40 years or in patients whose BCC was associated with
another tumor.
We also observed that the c.3944C/C genotype was
slightly less frequent in controls with light hair color
(P¼0.04, OR 0.44 [0.2–0.98]), but was not associated with
skin type or eye color. Importantly, the BCC risk attributable
to the c.3944C/C genotype persisted after stratification for
fair/light color (P¼0.006, OR 3.4 [1.42–8.24]) and skin types
I–II (P¼0.028, OR 2.27[1.1–4.73]).
Table 3. MC1R genotype in BCC patients and control subjects
BCC cases (n=126) Controls (n=151) P-value OR [95% CI]
(a) MC1R functional variants pooled
Wt/Wt 41 (33) 89 (59) Ref.
V/Wt 53 (42) 53 (35) 0.004 2.17 [1.28–3.68]
V/V 32 (25) 9 (6) o0.0001 7.72 [3.42–17.38]
(b) RHC and non-RHC alleles separately
Wt/Wt 41 (33) 89 (59) Ref.
RHC/Wt 16 (13) 11 (7) 0.0051 3.16 [1.35–7.40]
RHC/RHC 2 (2) 3 (2) 0.331 1.45 [0.23–9]
Non-RHC/Wt 37 (29) 41 (27) 0.022 1.96 [1.1–3.48]
Non-RHC/non-RHC 14 (11) 3 (2) o0.00011 6.72 [2.76–37.2]
RHC/non-RHC 15 (12) 4 (3) o0.00011 4.83 [2.54–26]
Ref.=reference; Wt=wild-type allele; V=variant alleles.
ORs compare Wt/V (heterozygotes) and V/V (two functional variants) to Wt/Wt. ORs are indicated with 95% CI.
1Fisher’s exact test. Significant associations are shown in bold characters.
Association of MC1R variants with the risk (OR) of BCC
Table 4. Role of MC1R variants on BCC risk after stratification on clinical risk factors
Subjects characteristics BCC (126) Controls (151)
MC1R genotype wt/wt Wt/V V/V wt/wt Wt/V V/V OR(1) V/wt versus wt/wt OR(2) V/V versus wt/wt
Skin type
III 16 10 7 39 21 2 1.16 [0.45–2–97] 8.63 [1.77–38.82]
IV 1 1 1 17 14 2 1.2 [0.11–12.7] 8.5 [0.64–124.35]
I 3 3 5 1 3 2 0.33 [0.03–4.28] 0.83 [0.08–10.48]
II 14 27 13 30 17 3 3.4 [1.42–8.13] 9.29 [2.4–35.2]
Hair color
Dark 7 9 1 29 16 2 2.33 [0.75–7.25] 2.07 [0.24–18.9]
Dark brown 8 10 5 34 23 3 1.85 [0.65–5.26] 7.08 [1.51–33.03]
Blond 4 10 7 6 4 0 3.75 [0.71–19.85] NA
Light brown 11 10 7 17 11 1 1.4 [0.45–1.34] 10.82 [1.85–74.82]
Red 1 1 2 0 1 3 NA NA
Eye color
Dark 15 11 10 52 38 7 1 [0.42–2.34] 4.95 [1.65–14.87]
Light 18 30 13 35 16 2 3.65 [1.6–8.32] 12.64 [2.82–55.05]
Lentigines
No 10 14 4 57 36 4 2.22 [0.9–5.43] 5.7 [1.33–24.72]
Yes 22 26 20 26 18 4 1.71 [0.75–3.88] 5.91 [1.82–18.94]
Wt=wild-type allele; V=variant alleles; NA=not applicable.
OR compare Wt/V (heterozygotes, OR no. 1) and V/V (two functional variants, OR no. 2) to Wt/Wt.
OR are indicated with 95% CI. Results are indicated by number of patients.
Significant associations are shown in bold characters.
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The distribution of genotypic frequencies of the second
PTCH polymorphism, ins18 bp 4IVS1-84, was not statistically
different in the cases and controls (P¼ 0.42).
Interaction between MC1R and PTCH variants on BCC risk
To test the interaction between MC1R and PTCH variants on
BCC risk, we considered as BCC risk factors the c.3944C/C
genotype of PTCH and functional MC1R variants as defined
in Materials and Methods. We then tested whether MC1R
genotype depends on PTCH genotype in the BCC patients.
The c.3944C/C genotype frequency was not significantly
different between BCC patients carrying a MC1R variant and
those that did do not carry one (54 vs 46% P¼0.45),
suggesting an independent effect of both genes on BCC risk.
However, the limited sizes of each subgroup need to take
these results cautiously.
Multiple logistic regression analyses
Interestingly, in multiple logistic regression analyses, which
take into account all these potential confounders, the
presence of MC1R variants remained an important BCC risk
factor (Table 6), together with fair pigmentation character-
istics and poor tanning response to UVR.
DISCUSSION
In this study, we have analyzed for the first time the
distribution of both MC1R variants and of two PTCH
polymorphisms in the French population. Our results confirm
the association of MC1R variants with the risk of developing
BCC in this population. Yet, a certain number of differences
from previous studies should be pointed out. In our
population, both non-RHC and RHC alleles were closely
associated with BCC risk (Table 3). The V60L and V92M
variants that have been reported to be low-penetrant RHC
alleles (Sturm et al., 2003b) and that are only slightly or not at
all associated with non-melanoma-skin cancer risk in the
Celtic population (Jones et al., 1999; Box et al., 2001) were
the most frequently observed variants in our population and
closely associated with BCC risk (Table 2). In the Australian
population, three RHC variants (D294H, R160W, and
R151C) were those most closely associated with BCC risk
(Box et al., 2001; Dwyer et al., 2004). In contrast, in our
series, only R151C was associated with BCC, but the lack of
association between the other RHC alleles – R142H, R160W,
and D294H – and BCC risk could be due to their low allelic
frequency, which would have made it necessary to study a
larger population. These differences might be related to the
specificity of the French population, which has a different
ancestry and a darker complexion than the other populations
studied, which were mainly of Celtic origin. In fact,
compared to the Celtic population, RHC alleles had a global
lower allelic frequency in both the French patients (11.2%)
and the controls (6.6%).
The number of MC1R variants also appeared to modulate
the risk of BCC, as the presence of at least two variants
increased the risk by a factor 3 compared to the presence of
only one MC1R variant (see Table 3). This genetic dosage
effect had previously been reported for the association
between MC1R and the risk of non-melanoma-skin cancer
(Bastiaens et al., 2001).
After stratification with known clinical risk factors for non-
melanoma-skin cancer (i.e. skin type, eye and hair color, and
Table 5. Association of Patched variant c. 3944C/T with BCC risk
c.3944C/T (rs357564)
BCC
(n=125) (a)
Controls
(n=151) (b) P OR1
MBCC
(n=102) P 0R1
SBCC
(n=23) P OR1
Genotype frequencies
Leu/Leu (c.3944 T/T) 15 (12) 24 (16) Ref. 12 (12) Ref. 3 (13) Ref.
Pro/Leu (c.3944 C/T) 46 (37) 74 (49) 35 (34) 11 (48)
Pro/Pro (c.3944 C/C) 64 (51) 53 (35) 0.007 1.94 [1.2–3.1]1 55 (54) 0.003 2.16 [1.3–3.6]1 9 (39) 0.7 1.19 [0.5–2.9]1
Allelic frequency2 0.7 0.6 0.016 0.71 0.008 0.63 0.65
HWE, Hardy–Weinberg equilibrium; MBCC=multiple BCC; Ref.=reference; SBCC=single BCC.
1Odd ratio was calculated by comparing the 3944C/C (Pro/Pro) genotype to the (3944C/T (Pro/Leu)+3944T/T (Leu/Leu)) genotypes.
2Allelic frequency of the major allele (C).
(a) P-value for HWE=0.55. (b) P-value for HWE=0.99.
Significant associations are shown in bold characters.
Table 6. Multiple logistic regression analysis of BCC
risk factors
Effect P-value OR
95% confidence
limit
Skin type I or II 0.03 2.11 1.08–4.14
MC1R variants 0.0044 2.53 1.34–4.8
PTCH c.3944 CC (1315Pro/Pro) 0.15 1.6 0.83–3
Light hair color 0.0021 2.9 1.47–5.7
Solar lentigines o0.0001 4.67 2.46–8.89
Logistic regression multiple analysis includes all clinical risk factors,
PTCH genotype Pro/Pro and MC1R variants; ORs are indicated with
95% CI.
Significant associations are shown in bold characters.
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the presence of solar lentigines), the effect of MC1R variants
on BCC risk persisted significantly (Table 4). This highlights
the importance of MC1R variants as independent BCC risk
factors, as previously noted in the Dutch and Australian
populations (Bastiaens et al., 2001; Box et al., 2001).
MC1R variants had no influence on the age at diagnosis of
BCC, the number of tumors or family history of BCC. This
contrasts with BCC patients from The Netherlands, in whom
the number of MC1R variants was significantly and indepen-
dently associated with a higher number of skin tumors
(Bastiaens et al., 2001). This suggests that additional genetic
factors might account for the difference in BCC susceptibility
in these populations. However, given the limited size of each
subgroup, these data must be viewed with some caution and
need to be confirmed in a larger set of patients.
In our population, the PTCH c.3944C/C genotype
(corresponding to Pro/Pro) was significantly overrepresented
in BCC patients, especially in the subgroup of patients with
multiple BCCs (Table 5). The frequency of the c.3944C/C
genotype has been shown to range from 30 to 65% across six
normal human populations (Asplund et al., 2005). However,
we do not yet know whether this variant is itself functional, or
is in linkage disequilibrium with a functional polymorphism.
No association with BCC risk could be demonstrated in a
relatively small series of 88 Swedish patients, despite the fact
that the c.3944C/C genotype was more frequent in the BCC
patients than in the controls (44 vs 35%) (Asplund et al.,
2005). However, this genotype was also more frequently
present in US or Swedish patients with multiple BCC tumors
(Asplund et al., 2005). Overall, these findings suggest that this
genotype could be a risk factor for the development of BCC in
the French population. However, some other studies do seem
to show a potential protective effect on BCC of some PTCH
haplotypes including this polymorphism in combination with
other variants (intron 15, (G2560þ 9) or exon 12, c.1686C)
(Strange et al., 2004a, b). This means that further work is
needed to clarify the role of this variant in genetic
predisposition to BCC.
In conclusion, our study confirms the importance of MC1R
variants among the BCC risk factors affecting the French
population, which include both RHC and non-RHC
alleles. Our work also suggests that PTCH gene exon 23
polymorphism c.3944C4T is involved in genetic suscept-
ibility to BCC. These findings make it possible to improve the
molecular identification of populations with a high risk of
developing BCC, and this could be helpful in adapting
appropriate preventive strategies.
MATERIALS AND METHODS
Study population
A prospective cohort of 126 patients with BCC and 151 controls
were recruited between 1998 and 2004 in order to study
environmental and genetic risk factors for BCC in the French
population. The study population consisted of patients aged 24–91
years with histologically proven BCCs. All the participants were
Caucasians recruited via the dermatology departments in four
hospitals in Paris (France): the Ambroise Pare´, Tarnier, Bichat
Claude-Bernard, and Saint-Louis Hospitals, and all had given
informed consent. The 126 patients were considered to be likely
to have a genetic predisposition to BCC on the basis of at least one of
the following criteria: familial BCC defined as the presence of a BCC
in at least two first- or second-degree relatives (n¼ 26), multiple BCC
(at least 2, n¼ 102), onset of BCC before the age of 40 years (n¼ 41),
BCC associated with another cancer (n¼ 20) (colon, two cases;
hematological malignancies, three cases; uterus, three cases; breast,
five cases; skin squamous cell carcinoma, two cases; prostate, three
cases; lung, one case; testis, one case). Since some patients had more
than one criteria the total numbers of cases is above 126.
Patients who fulfilled the usual criteria for nevoid basal cell
carcinoma syndrome (NBCCS) (Gorlin syndrome), or who were
organ transplant recipients or suffered from xeroderma pigmentosum
were excluded. None of the patients carried PTCH germline
mutations.
The control group, recruited during the same period, was
extended from one previously described (Matichard et al., 2004)
and was composed of 151 individuals who had no personal or family
history of skin cancer, who matched the patients in terms of age, sex,
and geographical residence, and had been referred by the same
departments and hospitals as the patients. The birthplace of the
parents and grandparents were recorded to ensure that all the
patients and control subjects were of Caucasian origin. All of the
patients had been born in France, and most of their parents and
grandparents (80%) were also all born in France. The remaining
parents and grandparents (20%) had been born elsewhere in Europe.
The Hospital Medical Ethics Committee (CCPPRB) approved the
study protocol. Informed consent was obtained from all the patients
and control subjects enrolled in the study. The study was conducted
in accordance with the Declaration of Helsinki Principles.
Participants were interviewed individually by a dermatologist,
and a total skin examination was performed to collect data, which
was recorded using a printed examination sheet. Information was
recorded about solar lentigines, and eye color (classified as dark
(brown or black) or light (blue, green/hazel, or gray)), and original
hair color during early adulthood (classified using five categories:
red, blond, light- or dark –brown, and black). Skin type was assessed
according to the modified classification of Fitzpatrick as follows:
always burns never tans (skin type I), always burns then tans (skin
type II), always tans sometimes burns (skin type III), and always tans
never burns (skin type IV) (Fitzpatrick, 1988). In addition, anatomical
location of the tumor, age at diagnosis, and histopathological data
were collected. The anatomical sites of BCC tumors were classified
as follows: head and neck, trunk, or limbs.
The final series analyzed comprised 277 subjects: 126 BCCs
patients and 151 controls. The mean age and sex ratio did not differ
in the two groups (Table 1). The BCC was of the superficial, nodular,
infiltrating, and sclerodermiform histological subtype in respectively
88, 41, 30, and 17 BCC patients. Tumors involved one body site in
58.5% of patients (head and neck in 37%; trunk in 19%; limbs in
2.5%), two body sites in 24.5% of patients (head and neck and trunk,
14%; trunk and limbs in 8%; head and neck and limbs, 2.5%) and
the three body sites (head and neckþ trunkþ limbs) in 17% of
patients.
Detection of MC1R gene variants
Genomic DNA was isolated from peripheral blood leukocytes of all
participants by routine methods (Miller et al., 1988). The MC1R
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coding sequence was amplified by PCR with two overlapping pairs
of primers, and sequenced as previously described (Matichard et al.,
2004).
Genotyping of PTCH variants
The non-synonymous polymorphism in exon 23 of PTCH,
c.3944C4T (L1315P, rs 357564) was genotyped using Taqman
probe technology (Applied Biosystems, Foster City, CA, USA).
Briefly, this product uses the 50 nuclease assay to discriminate
between two alleles of a specific single nucleotide polymorphism for
use in genotyping studies. Each assay is a 20 mix of forward
primer, reverse primer, 6FAMTM dye – minor grove binder (MGB)-
labeled probe, and VICs dye – MGB-labeled probe. Each probe
binds preferentially to one of the alleles. The detection of fluorescence
was performed using a 7000 automate (Applied Biosystems).
A new polymorphism of PTCH, an 18 bp insertion localized
83 bp upstream from the donor splicing site of exon 2, was simply
genotyped by PCR amplification (primer sequence (50-30), forward
CTG CGG CCC GGC TTT ATG AC, reverse GTG TGC GCT GGC
GAA TAT CTC TAT C), and migration on a 2% agarose gel. PCR
conditions included 35 denaturing cycles at 951C for 30 seconds,
annealing at 601C for 30 seconds, elongation at 721C for 45 seconds.
Statistical analyses
Statistical analyses were performed using SAS software release 8.2
(SAS institute, Cary, NC). w2 analysis (plus Fisher’s exact test when
necessary) was used to compare clinical and genetic characteristics
between BCC patients and controls.
For clinical analysis, the BCC usual risk factors (skin type, solar
lentigines, eye and hair colors) were compared between cases and
controls.
For genetic analysis, only the MC1R polymorphisms considered
to be functional were retained. These consisted of the following
categories of polymorphisms:
(1) MC1R variants that were unable to stimulate cAMP production
as strongly as the wild-type receptor in response to a-MSH
stimulation (Frandberg et al., 1998; Healy et al., 2001; Jimenez-
Cervantes et al., 2001a, b; Schioth et al., 1999),
(2) MC1R variants showing a decreased a-MSH binding affinity
(Jimenez-Cervantes et al., 2001a; Ringholm et al., 2004),
(3) MC1R variants previously shown to be associated with
melanoma risk (Valverde et al., 1996; Palmer et al., 2000;
Kennedy et al., 2001),
(4) MC1R variants previously shown to be associated with the RHC
phenotype (reviewed in Sturm, 2002),
(5) MC1R variants predicted to be damaging by the Polyphen
program and
(6) an MC1R single nucleotide insertion producing a frameshift
mutation that results in a prematurely terminated, non-
functioning receptor.
The T95M, R163Q, V180L, and R223Q MC1R variants did not
meet these criteria and were therefore considered to be wild type
(Table 2). This conservative approach allowed us to include all the
patients and controls in the analysis.
Firstly, univariate analyses were used to compare genetic risk
factors (MC1R genotype) in BCC patients and controls.
Secondly, multiple logistic regression analysis was performed to
take into account potential confounders among the clinical risk
factors, such as skin type, eye and hair colors, and solar lentigines.
OR were calculated with their 95% confidence interval (CI). All
significance levels reported were two sided and set at Po0.05.
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